Cell-Penetrating Peptides Enable Delivery of Degrader Drug Components Inside Living Cells | Research

The takeaway

Cell-penetrating peptide conjugates successfully delivered degron peptides into cells and engaged the E3 ligase SPSB2, advancing peptide-based tools for PROTAC drug development.

Cellular delivery + target engagement confirmed
CPP-degron conjugates successfully crossed cell membranes and engaged the SPSB2 E3 ligase target inside living cells, demonstrated by both confocal microscopy and BRET-based functional assays.

What the researchers found

Researchers developed peptide-based tracers for the E3 ligase SPSB2, a key component in designing PROTAC degrader drugs. Degron peptide sequences recognized by SPSB2 were conjugated with cell-penetrating peptides (CPPs) to achieve cellular delivery. A high-resolution crystal structure was obtained, and biophysical techniques confirmed binding. Confocal microscopy and BRET-based assays demonstrated successful cellular delivery and potent target engagement. This provides a blueprint for developing peptide-based tools to evaluate new E3 ligase targets for PROTAC drug design.

Why it matters

PROTACs are among the most exciting new drug modalities — they hijack the cell's protein disposal system to destroy disease-causing proteins. But designing PROTACs requires new E3 ligase ligands, and many potential ligands based on natural degron peptides can't enter cells. This study solves that delivery problem using cell-penetrating peptides, expanding the toolkit for PROTAC drug development and potentially enabling a new generation of targeted protein degradation therapies.

The numbers in context

High-resolution crystal structure obtained · multiple CPP conjugates tested · BRET-based cellular TE assays · confocal microscopy delivery confirmation · SPSB2 E3 ligase targeted

How the study worked

Degron peptide sequences for SPSB2 were conjugated with various polycationic cell-penetrating peptides. A crystal structure of the SPSB2-degron complex was determined. Biophysical techniques assessed how each modification affected binding. Cellular delivery was confirmed by confocal microscopy, and target engagement was measured using BRET-based assays in living cells.

Who was studied

In vitro biochemical and cellular assay study (no biological subjects)

What this study cannot tell us

This is a proof-of-concept study for target engagement methodology rather than a therapeutic study. The SPSB2 system served as a model; applicability to other E3 ligases needs validation. The CPP-degron conjugates were used as research tools, not as therapeutic candidates. In vivo delivery and pharmacokinetics of the peptide conjugates were not assessed.

How to read the evidence

This is a methods development study combining structural biology (crystal structure), biophysics, and cellular assays. The technical rigor is high, but this is a tool-building study rather than a therapeutic development study.

When this study was published

Published in 2026, this represents the cutting edge of peptide-based tools for the rapidly growing PROTAC and targeted protein degradation field.

The bigger picture

Targeted protein degradation via PROTACs is one of the fastest-growing areas in drug development, with multiple compounds in clinical trials. The field's expansion depends on discovering new E3 ligase ligands — currently only a handful are available. This study's peptide-based approach to evaluating E3 ligase engagement could dramatically accelerate the identification of new ligases and ligands, fueling the next wave of PROTAC therapeutics for diseases from cancer to neurodegeneration.

Questions still open

Can CPP-degron conjugates serve as functional PROTACs themselves, or are they primarily useful as research tools?
How many new E3 ligases could be unlocked for PROTAC drug design using this peptide-based target engagement approach?
Could this delivery strategy work for other types of peptide-based drugs that struggle with cell permeability?

Common questions

What are PROTACs and why do they need peptide-based tools?

PROTACs (PROteolysis TArgeting Chimeras) are a new type of drug that works by tagging disease-causing proteins for destruction by the cell's natural recycling system. They need two components: one that binds the disease protein and one that binds an E3 ligase (the cell's protein destruction machinery). Degron peptides — natural protein sequences recognized by E3 ligases — are starting points for designing the E3 ligase-binding component, but testing them inside cells has been difficult until now.

Why can't degron peptides enter cells on their own?

Degron peptides are typically highly polar molecules with electrical charges that prevent them from crossing the oily cell membrane. Cell-penetrating peptides (CPPs) solve this by providing a positively charged 'escort' that can traverse the membrane and carry the cargo peptide inside. This conjugation strategy is widely used in peptide drug delivery.

Read the original research

Overcoming Ligand Discovery Challenges: Developing Peptide-Based Tracers for SPSB2.

ACS chemical biology, 21(2), 274-283

View on PubMed ↗Publisher’s paper ↗

Citation

Lenz, Christopher; Elson, Lewis; Dopfer, Johannes; Farges, Frederic; Krämer, Andreas; Löhr, Frank; Müller, Susanne; Guéret, Stéphanie M; Waldmann, Herbert; Dötsch, Volker; Saxena, Krishna; Knapp, Stefan. (2026). Overcoming Ligand Discovery Challenges: Developing Peptide-Based Tracers for SPSB2.. ACS chemical biology, 21(2), 274-283. https://doi.org/10.1021/acschembio.5c00702